Stocktoria
YD Bio Ltd YDES
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2025-08-29
YD Bio Ltd financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $596,817 | $510,360 |
| Gross profit | $167,410 | $155,356 |
| R&D expense | $1.6M | $491,353 |
| Operating income | -$5.3M | -$1.5M |
| Income tax | -$1,531 | $25,080 |
| Net income | -$8.3M | -$1.4M |
| EPS (diluted) | $-0.12 | $-0.02 |
| Operating cash flow | -$6.6M | -$1.2M |
| Free cash flow | -$8.0M | -$1.3M |
| Cash & equivalents | $6.0M | $3.1M |
| Inventory | $1.9M | $37,335 |
| Total assets | $13.8M | $6.9M |
| Total liabilities | $16.6M | $273,980 |
| Shareholders' equity | -$2.9M | $6.6M |
Source: SEC EDGAR filings · CIK 0002011674 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.